CL2007001325A1 - Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades. - Google Patents

Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades.

Info

Publication number
CL2007001325A1
CL2007001325A1 CL200701325A CL2007001325A CL2007001325A1 CL 2007001325 A1 CL2007001325 A1 CL 2007001325A1 CL 200701325 A CL200701325 A CL 200701325A CL 2007001325 A CL2007001325 A CL 2007001325A CL 2007001325 A1 CL2007001325 A1 CL 2007001325A1
Authority
CL
Chile
Prior art keywords
compounds
arterioesclerosis
illnesses
bicycles
pharmaceutical composition
Prior art date
Application number
CL200701325A
Other languages
English (en)
Inventor
Masashi Marsuuta Naoko Kishida
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609268.8A external-priority patent/GB0609268D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2007001325A1 publication Critical patent/CL2007001325A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
CL200701325A 2006-05-10 2007-05-09 Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades. CL2007001325A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0609268.8A GB0609268D0 (en) 2006-05-10 2006-05-10 Organic compounds
US86648006P 2006-11-20 2006-11-20
US89614207P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
CL2007001325A1 true CL2007001325A1 (es) 2008-07-18

Family

ID=38445602

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200701325A CL2007001325A1 (es) 2006-05-10 2007-05-09 Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades.

Country Status (17)

Country Link
US (2) US8232403B2 (es)
EP (1) EP2024356A1 (es)
KR (1) KR101172120B1 (es)
AR (1) AR060873A1 (es)
AU (1) AU2007247385B2 (es)
CA (1) CA2650954C (es)
CL (1) CL2007001325A1 (es)
CR (1) CR10420A (es)
EC (1) ECSP088891A (es)
GT (1) GT200800242A (es)
IL (1) IL195010A0 (es)
MA (1) MA30427B1 (es)
MX (1) MX2008014284A (es)
NO (1) NO20084912L (es)
TN (1) TNSN08444A1 (es)
TW (1) TW200813009A (es)
WO (1) WO2007128568A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101238525B1 (ko) 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP2009522224A (ja) * 2005-12-29 2009-06-11 ノバルティス アクチエンゲゼルシャフト コレステリルエステル輸送タンパク質（ｃｅｔｐ）の阻害剤としてのピリジニルアミン誘導体
AR060873A1 (es) * 2006-05-10 2008-07-16 Novartis Ag Derivados biciclicos como inhibidores de cetp
BRPI0711447A2 (pt) * 2006-05-11 2011-11-08 Novartis Ag compostos orgánicos
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
AU2008241904B2 (en) 2007-04-13 2012-06-07 Kowa Company, Ltd. Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN102300839B (zh) 2008-11-28 2014-12-10 兴和株式会社 反式-{4-[(烷基氨基)甲基]环己基}乙酸酯的制备方法
CA2772714C (en) * 2009-09-03 2017-09-26 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
ES2683350T3 (es) 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
KR101774223B1 (ko) 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
BR112015011515A2 (pt) * 2012-11-19 2017-08-22 Dr Reddy´S Laboratories Ltd Composições farmacêuticas de inibidores de cetp
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US20160000799A1 (en) * 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
EA201690282A1 (ru) 2013-07-25 2016-09-30 Новартис Аг Биоконъюгаты синтетических апелиновых полипептидов
JP6501775B2 (ja) 2013-07-25 2019-04-17 ノバルティス アーゲー 心不全治療用の環状ポリペプチド
MA41580A (fr) 2015-01-23 2017-11-29 Novartis Ag Conjugués d'acides gras de l'apeline synthétique présentant une demi-vie améliorée
MX2022007178A (es) * 2019-12-11 2022-07-13 Ryvu Therapeutics S A Compuestos heterociclicos como moduladores del estimulador de genes de interferon (sting).

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6476057B1 (en) * 1999-09-23 2002-11-05 G.D. Searle & Co. Use of substituted N, N-disubstituted cycloalkyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
CN1468241A (zh) * 2000-08-07 2004-01-14 作为gabaa受体配体的杂环化合物
DE60311821T2 (de) * 2002-08-30 2007-10-31 Japan Tobacco Inc. Dibenzylaminverbindung und deren medizinische verwendung
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
MXPA05010456A (es) 2003-03-28 2006-03-21 Pfizer Prod Inc Compuestos de quinolina y quinoxalina.
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005100298A1 (en) 2004-04-13 2005-10-27 Merck & Co., Inc. Cetp inhibitors
WO2006056854A1 (en) 2004-11-23 2006-06-01 Pfizer Products Inc. Dibenzyl amine compounds and derivatives
US7668830B2 (en) 2004-11-29 2010-02-23 Nokia Corporation Access rights
KR101238525B1 (ko) * 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
KR101184807B1 (ko) 2005-01-06 2012-09-20 톰슨 라이센싱 디지털 광 프로젝션 시스템에서 레인보우 아티팩트를줄이는 방법 및 장치
CN101218497B (zh) 2005-07-07 2012-04-25 索尼株式会社 利用瞬逝光的物质信息获取方法和物质信息测量装置、以及碱基序列确定方法和装置
US7573978B2 (en) 2005-07-11 2009-08-11 University Of Florida Research Foundation, Inc. Variable feathering field splitting for intensity modulated fields of large size
JP4981814B2 (ja) * 2005-12-28 2012-07-25 ドクター・レディーズ・ラボラトリーズ・リミテッド 選択的なベンジルアミン誘導体およびコレステロールエステル転写タンパク質抑制剤としてのその有用性
JP2009522224A (ja) * 2005-12-29 2009-06-11 ノバルティス アクチエンゲゼルシャフト コレステリルエステル輸送タンパク質（ｃｅｔｐ）の阻害剤としてのピリジニルアミン誘導体
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
AR060873A1 (es) * 2006-05-10 2008-07-16 Novartis Ag Derivados biciclicos como inhibidores de cetp
BRPI0711447A2 (pt) * 2006-05-11 2011-11-08 Novartis Ag compostos orgánicos
AU2007321283A1 (en) * 2006-11-15 2008-05-22 Novartis Ag Heterocyclic derivatives as CETP inhibitors
AU2007321197A1 (en) * 2006-11-15 2008-05-22 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US8410275B2 (en) 2013-04-02
WO2007128568A1 (en) 2007-11-15
AU2007247385A1 (en) 2007-11-15
AR060873A1 (es) 2008-07-16
IL195010A0 (en) 2009-08-03
KR20090017580A (ko) 2009-02-18
CR10420A (es) 2009-02-02
CA2650954A1 (en) 2007-11-15
AU2007247385B2 (en) 2011-07-14
NO20084912L (no) 2009-02-03
KR101172120B1 (ko) 2012-08-10
US8232403B2 (en) 2012-07-31
EP2024356A1 (en) 2009-02-18
GT200800242A (es) 2009-04-29
US20120225874A1 (en) 2012-09-06
MA30427B1 (fr) 2009-05-04
US20090227580A1 (en) 2009-09-10
MX2008014284A (es) 2008-11-18
TNSN08444A1 (en) 2010-04-14
TW200813009A (en) 2008-03-16
CA2650954C (en) 2014-02-11
ECSP088891A (es) 2008-12-30

Similar Documents

Publication Publication Date Title
CL2007001325A1 (es) Compuestos derivados de biciclos, inhibidores de cept; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, entre otras enfermedades.
CL2007002107A1 (es) Compuestos derivados de bencil piperidin-1-il amina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hiperlipidemia, arterioesclerosis, ateroesclerosis, vasculopatia periferica, dislipidemia, entre otras enfermedades.
CL2007003470A1 (es) Compuestos derivados de urea; composicion farmaceutica que comprende a dichos compuestos; y su uso como antibacterianos.
BRPI0809977A2 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
BRPI0716171A2 (pt) composto, composiÇço farmacÊutica e uso de um composto.
CL2008000094A1 (es) Compuestos derivados de pteridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para aumentar la vasodilatacion.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2008000754A1 (es) Compuesto derivado de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso para tratar cancer y trastornos hiperproliferativos.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
CL2008000369A1 (es) Compuestos derivados de piridopirimidinonas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar dolor, depresion, enfermedades cardiovasculares, enfermedades respiratorias y enfermedades psiquiatricas.
CL2008000197A1 (es) Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2008000784A1 (es) Compuestos amino-5-[-4-(diflourometoxi) fenil sustituido]-5-fenilmidazolona, inhibidores de b-secretasa; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar alzheimer, deterioro cognitivo, sindrome de down, disminucion co
CL2007003232A1 (es) Compuestos derivados de 5-hidroximetil oxazolidin-2-ona; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar y prevenir infecciones bacterianas.
BRPI0815170A2 (pt) Composição farmacêutica que compreende um inibidor de sglt 2
CL2007002916A1 (es) Compuestos derivados de pirazoliltienopiridinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en la inhibicion de escaras.
CL2007003725A1 (es) Composicion herbicida que comprende un compuesto derivado de isoxazolina; y metodo para preparar la composicion herbicida.
BRPI0810696A2 (pt) Composto, composição farmacêutica, e, uso de um composto
CL2007002446A1 (es) Compuestos derivados de morfolino pirimidina; composicion farmaceutica; y su uso para preparar un medicamento para producir un efecto antiproliferante.
CL2007003154A1 (es) Compuestos derivados de pirazolina; composicion farmaceutica que comprende a los compuestos; y uso para tratar afecciones cardiovasculares, renales, hepaticas y vasculares entre otras.
CL2007003565A1 (es) Compuestos derivados de piperidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion vih.
CL2007002021A1 (es) Compuestos derivados de oxoisoindol; composicion farmaceutica que los comprende; y su uso para tratar arritmias.
CL2008000794A1 (es) Compuestos derivados de biarilo y heteroarilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno de hierro.
CL2007003212A1 (es) Compuestos derivados de imidazopirazinas, inhibidores de proteina quinasa; composicion farmaceutica que los comprende; y su uso para tratar cancer.
CL2008000029A1 (es) Compuestos derivados de 1-bencil imidazol, inhibidores de eg-5; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BRPI0810399A2 (pt) Composto, composição farmacêutica que o contém e uso do mesmo